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Abstract
Background: Methylation levels of genomic repeats such as long interspersed nucleotide elements (LINE-1) are
representative of global methylation status and play an important role in maintenance of genomic stability. The objective of
the study was to assess LINE-1 methylation status in colorectal cancer (CRC) in relation to adenomatous and malignant
progression, tissue heterogeneity, and TNM-stage.
Methodology/Principal Findings: DNA was collected by laser-capture microdissection (LCM) from normal, adenoma, and
cancer tissue from 25 patients with TisN0M0 and from 92 primary CRC patients of various TNM-stages. The paraffin-
embedded tissue sections were treated by in-situ DNA sodium bisulfite modification (SBM). LINE-1 hypomethylation index
(LHI) was measured by absolute quantitative analysis of methylated alleles (AQAMA) realtime PCR; a greater index indicated
enhanced hypomethylation. LHI in normal, cancer mesenchymal, adenoma, and CRC tissue was 0.38 (SD 0.07), 0.37 (SD
0.09), 0.49 (SD 0.10) and 0.53 (SD 0.08), respectively. LHI was significantly greater in adenoma tissue compared to its
contiguous normal epithelium (P=0.0003) and cancer mesenchymal tissue (P,0.0001). LHI did not differ significantly
between adenoma and early cancer tissue of Tis stage (P=0.20). LHI elevated with higher T-stage (P,0.04), was significantly
greater in node-positive than node-negative CRC patients (P=0.03), and was significantly greater in stage IV than all other
disease stages (P,0.05).
Conclusion/Significance: By using in-situ SBM and LCM cell selection we demonstrated early onset of LINE-1 demethylation
during adenomatous change of colorectal epithelial cells and demonstrated that LINE-1 demethylation progression is linear
in relation to TNM-stage progression.
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Introduction
Approximately 17–18% of the human genome consists of long
interspersed nucleotide element (LINE-1) repeats. Roughly
500,000 truncated and 3,000 to 5,000 full length LINE-1
sequences are present throughout the genome [1]. In normal
somatic cells, LINE-1s are heavily methylated, restricting activities
of retrotransposal elements and thus preventing genomic instabil-
ity [2,3]. LINE-1 sequences are moderately CpG rich, and most
methylated CpGs are located in the 59 region and can behave as
internal promoters [2]. LINE-1 methylation status is thought to
represent the genome-wide DNA methylation status, since LINE-1
sequences are highly repeated, widely interspersed human retro-
transposons. Various studies have shown a relation of important
genomic events in colorectal carcinogenesis to LINE-1 methyla-
tion. For example, 18q loss of heterozygosity (LOH) (+) colorectal
cancer (CRC) show a lower mean LINE-1 methylation level [4].
An inverse relation has been reported between LINE-1 methyl-
ation and microsatellite instability (MSI)+/CpG island methylator
phenotype (CIMP)+/BRAF V600E mutation CRC [5,6]. There
has recently been reported a significant inverse correlation
between levels of LINE-1 methylation and the total number of
chromosomal aberrations, including both losses and gains in
gastrointestinal stromal tumors (GIST) [7]. Regarding CRC,
Bariol et al. revealed that the global DNA hypomethylation level
was greater in neoplastic lesions (including hyperplastic polyps and
adenoma) than in normal mucosa [8].
An important problem in the assessment of LINE-1 methylation
status in CRC is that CRC is highly heterogeneous and contains
various infiltrating cells such as stromal cells, lymphocytes, and
blood vessels. The stromal component and extent of lymphocyte
infiltration varies greatly among CRCs. This heterogeneity may
confound molecular analysis, especially of LINE-1 methylation
status, as LINE-1 is methylated in normal cells. In order to obtain
accurate interpretations, it is therefore necessary to specifically
isolate tumor cells from tissue specimens. Early stage CRC
primary tumor analysis without histopathology-directed microdis-
section for assessment of genomic methylation status is not
accurate. This is particularly a problematic issue when assessing
CRC progression and when comparing adenoma to cancer tissue.
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therefore, we developed a practical approach. We utilized laser–
capture microdissection (LCM) to harvest the cells of interest
directly without contamination of non-cancer cells. Sodium
bisulfite modification (SBM) of genomic DNA is a commonly
used method to discern methylation status of CpG islands [9].
Conventional SBM methods result into 84% to 96% loss of sample
DNA [10]. This significant loss of template DNA necessitates high
volumes of starting tissue sample. To reduce the loss of sample
DNA from cells collected by LCM, we developed an in-situ SBM
protocol. DNA was modified while the captured cells are still
attached on the LCM cap.
Numerous studies have been reported identifying CRC-
associated epigenetic aberrations such as promoter region
hypermethylation of tumor suppressor genes. Another character-
istic alteration in CRC regarding DNA methylation status is global
hypomethylation [11,12]. The progression of LINE-1 hypomethy-
lation level during the development of CRC malignancy and the
progression of disease has not been rigorously assessed. Deter-
mining the histopathology associated with the onset of loss of
LINE-1 methylation and the trend of LINE-1 methylation along
the axis of disease stage progression could further clarify the role of
LINE-1 hypomethylation in CRC disease. In this study, LCM, in-
situ SBM, and absolute quantification of methylated alleles
(AQAMA) were utilized in combination on specimens from
patients with adenomas containing in situ invasive adenocarcinoma
(Tis) and patients with more advanced CRC. This allowed
successful accurate analysis of LINE-1 hypomethylation levels
during primary tumor progression between progressive T-stages,
node positive versus node negative disease, and distant metastatic
versus local and locoregional disease.
Results
AQAMA linearity for LINE-1 methylation level assessment
First, we evaluated the accuracy of AQAMA in assessing various
levels of LINE-1 methylation. The major advantage of AQAMA is
that the quantitative measurement of methylated and unmethy-
lated alleles is performed in a single PCR reaction, providing
excellent control compared to two separate PCR reactions for
methylated and unmethylated allele analysis. The quantification is
absolute with standard curves to determine the copy number. For
a negative control, the assay reaction contained universal
unmethylated control DNA that was synthesized as described in
a previously published study [13]. For a positive control, we used
universal methylated control DNA extracted from peripheral
blood lymphocytes from a healthy donor and treated with sssI
methyltransferase. For this study, we prepared stepwise mixtures of
the methylated and unmethylated cDNA standard and measured
them as samples with unknown methylation level. The linearity of
AQAMA assay for LINE-1 methylation level (Figure 1) was
evaluated by Pearson’s coefficient of linearity: 0.99 (P,0.001),
which showed high accuracy in discriminating LINE-1 methyla-
tion level differences.
Optimization of in-situ SBM settings
LCM was performed to harvest cells of interest (Figure 2a)t o
obtain accurate representation of cells in question for successful





2 harvested from 4 mm-thick paraffin-embedded
archival tissue (PEAT) were tested. Through analysis, we
established that 2610
5 mm
2 of 4 mm-thick PEAT results in about
10
5 copy numbers of LINE-1 DNA. This provided significant
reproducible levels of DNA LINE-1 methylation assay. After
LCM, in-situ SBM was optimized in a similar manner as was
performed in the previous studies of on-slide SBM using specific
genomic sequence amplification [14]. The conversion rates of
modified DNA by in-situ SBM were 18.4614.9%, 87.867.8% and
94.462.1% at incubation setting of 60uC for 2, 4 and 8 hrs,
respectively (Figure 2b). The conversion rates increased with
increase in duration of incubation, whereby after 8 hrs it reached
about 95%. The yield of total DNA (modified and unmodified
DNA) did not decrease with increasing incubation time up to 8 hrs
(Figure 2c). From these results, an incubation setting of 60uC for
8 hrs was chosen as optimal for in-situ SBM.
LINE-1 hypomethylation levels during CRC progression
Twenty-five patients with TisN0M0 lesions with presence of
normal, adenoma (low or intermediate grade) and Tis cancer cells
on the same tissue section were selected. Using LCM, four
different tissue samples (normal mucosa, adenoma, cancer, and
cancer mesenchymal tissue) were collected from each patient. In-
situ SBM and LINE-1 AQAMA assay were performed on each
sample. The level of LINE-1 hypomethylation (LHI) was
calculated as Qunmeth/(Qunmeth + Qmeth), where Qunmeth and
Qmeth are the absolute copy numbers of unmethylated and
methylated LINE-1, respectively. In normal mucosa adjacent to
tumor lesions and cancer mesenchyme, the average LHI was
0.382 and 0.366, respectively. There was no difference of LHI
between cancer mesenchyme and normal mucosa adjacent to
tumor. LHI was significantly greater in the contiguous adenoma
and cancer tissue of early stage than in normal mucosa (mean
LHI=0.49, 0.52, and 0.38, respectively) (Figure 3). From these
results, we concluded that LINE-1 hypomethylation occurs in the
early stage of CRC tumorigenesis. Furthermore, these experiments
demonstrated the necessity of using detailed procedures for DNA
collection when analyzing LINE-1 methylation levels, such as
target cell isolation, by LCM. On the basis of this, LCM was used
for DNA sample collection for all experiments in our studies.
LINE-1 hypomethylation and tissue heterogeneity
In the analysis of LHI of normal, cancer mesenchymal,
adenoma, and CRC tissue, was 0.38 (SD 0.07), 0.37 (SD 0.09),
0.49 (SD 0.10) and 0.53 (SD 0.08), respectively. To test whether
there is heterogeneity of LINE-1 hypomethylation within a tumor,
20 T3N0 tumors were selected for analysis. Sample DNA was
collected from the luminal surface and the deepest invasional site
Figure 1. AQAMA LINE-1 assay accuracy. Plot of measured (boxes)
and expected (x) values showing accuracy of the AQAMA LINE-1 assay.
doi:10.1371/journal.pone.0018884.g001
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The mean LHI was 0.58 in the surface and 0.54 in the deepest
loci. LHIs were similar in the surface and in the deepest loci and
tumor heterogeneity of LINE-1 hypomethylation was not
observed.
LINE-1 hypomethylation and CRC stage
To assess the alteration of LINE-1 hypomethylation levels
according to tumor progression, the correlation between Dukes
stages and LHI was analyzed. Dukes A (n=38), Dukes B (n=18),
and Dukes C (n=29) samples were selected (Figure 5c). The
mean LHI in Dukes A, B, and C was 0.533, 0.607, and 0.621,
respectively. Dukes B and C tumors showed significantly greater
Figure 2. Representations of LCM combined with in-situ SBM optimization studies. A shows specific pick-up of target cells by LCM. B and
C show results for DNA conversion rate (%) and for DNA content (610
4 copy numbers), respectively, in 8 different samples at 3 different incubation
periods.
doi:10.1371/journal.pone.0018884.g002
Figure 3. LHI assessment in normal large bowel epithelium,
adenomatous cells, cancer cells (Tis) and CRC mesenchymal
cells.
doi:10.1371/journal.pone.0018884.g003
Figure 4. LHI analysis of CRC tumors. Measured LHI values in T3N0
CRC tumors comparing cells obtained from the surface luminal tumor
area to the deep invasion tumor area.
doi:10.1371/journal.pone.0018884.g004
LINE-1 Methylation in Colorectal Cancer
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18884LHI than Dukes A tumors. The relation between LINE-1
methylation and T-stage (T1 (n=24), T2 (n=21), T3 (n=21),
and T4 (n=26)) as well as N-stage (N0 (n=57) and N1 (n=35))
were analyzed. The increase of LHI according to tumor invasion
(Figure 5a) and the difference of LHIs between lymph node
positive and negative cases (Figure 5b) were assessed. The mean
LHI of T1, T2, T3, and T4 was 0.50, 0.58, 0.60, and 0.65,
respectively. LHI was significantly greater (P=0.03) for cases with
positive lymph nodes (LHI=0.64) than negative lymph nodes
(LHI=0.54). The prediction of nodal status would be the most
clinically relevant and therefore a receiver operating curve (ROC)
was analyzed to distinguish if node metastasis positive can be a
prognostic indicator of the primary CRC by means of LHI
(Figure 6). T-stage advancement correlated significantly with
increasing LHI (P=0.01). We also analyzed cases with distant
disease spread (Dukes D, n=6), and these cases showed
significantly greater LHI compared to Dukes C CRCs (P=0.05)
alone and to all other Duke stages (P,0.0001). A ROC was
plotted to show the accuracy for prediction of nodal involvement
by LHI (Figure 6). This showed that the predictive value had a
sensitivity of 0.77 with a specificity of 0.62. There was significantly
lower LHI for right-sided versus left-sided colon (P,0.05).
However, no significant differences were observed between LHI
for differentiation status or gender.
These analyses showed a positive linear relation between
progression of LINE-1 hypomethylation and CRC stage
progression.
Discussion
The alteration of DNA methylation patterns has been studied in
many types of cancer [15]. Hypermethylation of specific cancer-
associated gene promoter regions and global DNA hypomethyla-
tion during tumor progression has been now shown as a significant
property of cancers [16,17]. Hypomethylation of the LINE-1
DNA repeat which forms 20% of the genome has been suggested
as a surrogate for global DNA hypomethylation [5,18,19,20].
Yang et al. showed that genome-wide methylation can be
estimated by assessment [21]. Alu repeats are SINEs, more
complex, and diverse than LINEs. Reliable methylation assays to
study Alu are not well substantiated. An accurate assay
representative for global methylation phenomenon does not exist;
however, LINE-1 may serve well as a surrogate.
LINE-1 hypomethylation is not specific for cancer cells, and
about one third of LINE-1 is unmethylated in normal mucosa and
cancer mesenchymal cells [22,23]. The possible contamination of
specimen DNA that consists of cancer along with mesenchymal
cells, such as fibroblasts or lymphocytes, may therefore cause
inaccurate results. For this reason, especially regarding LINE-1
methylation analysis, accurate isolation of target cells is highly
important. To minimize the contamination and obtain cells of
interest only, we successfully integrated LCM in LINE-1
methylation analyses in this study. We assessed in-situ SBM
combined with LCM as an approach to improve the DNA
methylation assay efficiency, which enables evaluation of cells
from specific histopathologically defined target regions of very
early stage primary CRC development. A recent study has
provided some evidence that results are comparable whether
macrodissection or LCM is used [24]. However, this is highly
dependent on the sensitivity of the assay. The concept of LCM,
however, is state-of-the-art and superior to macrodissection when
small targeted tissue input specimen for DNA analysis is desired.
First, when early-stage small lesions need to be assessed and only
small areas of specific cancer cells are available for analysis, the
microscopy-guided cell pick-up provides precision and control of
the input sample DNA. Second, LINE-1 methylation is not
cancer-specific and, as our results show, is found in cancer stromal
Figure 5. Measured LHI values comparisons between clinical disease stage classifications. In A, B and C differences are shown between
Duke’s stage, T-stage and N-stage, respectively.
doi:10.1371/journal.pone.0018884.g005
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ronment and tumor stromal heterogeneity, it is highly important to
perform LCM analysis for specific tissue DNA retrieval. Also,
LINE-1 methylation would be expected to vary in adjacent
‘‘normal’’ cells of a primary tumor since light microscopy
pathology analysis is not always accurate to identify early stage
cancer cell transformation.
In-situ SBM was designed based on on-slide SBM [14] which
was adapted from a concept as reported by Nuovo et al [25]. On-
slide SBM is a powerful procedure for the methylation analysis
using PEAT; however, after on-slide SBM the specimen becomes
too adhesive to the glass slide, making it difficult for LCM to
efficiently capture target cells at times. In-situ SBM eliminates the
numerous DNA isolation and purification steps of classic SBM,
which are the main cause of DNA loss when assessing low amounts
of DNA from limited number of cells. Our study describes in situ
treatment of tissue/cells directly by bisulfite assay integrated with
LCM. A limitation of the assay is that analysis of methylation
status of single cells still remains difficult due to the DNA
degrading nature of the SBM protocol and limited DNA for
methylation analysis.
Combining LCM, in-situ SBM, and AQAMA assay, LINE-1
hypomethylation was demonstrated in low to intermediate grade
adenoma, an early stage of colorectal tumorigenesis as previously
shown [5,6]. A significant decrease in LINE-1 methylation was
measured comparing adenoma with the adjacent normal epithe-
lium. No significant difference was shown when the adenoma was
compared to the contiguous cancerous Tis stage tissue which was
also recently reported in by Kwon et al [26]. This result differs
from studies by Ibrahim et al. and by Irahara et al. that found
significant differences of LHI between colorectal adenomas and
CRC [24,27]. It is important to note that these studies did not
specify the TNM-stage of the samples. The non-significant
difference between adenoma and cancer tissues in our study is
explained by the use of a heterogeneous group of cancer tissues
from the earliest cancer stage (in situ carcinoma, Tis). Our results
confirm that LINE-1 methylation levels vary in different TNM-
stages. When LHI in adenomas were compared to more advanced
stage CRC samples in our study the differences were significant
(data not shown). This demonstrates that unmethylated LINE-1
may not play an important role during the process when adenoma
cells gain their first invasive activity.
The increased heterogeneity found in larger, advanced lesions is
an indication that there exist subgroups of CRC that are able to
maintain methylation of LINE-1. On the other hand, we observed
that two Dukes stage D cases had an LHI of 0.9 which was only
seen in this subgroup. Heterogeneity is a known clinical problem
as disease outcome varies widely for CRC patients with the same
TNM-stage. The diversity of the LHIs within the various stages in
our study may reflect this. The mechanisms that control
maintenance of LINE-1 methylation and how they influence
tumor progression is still unknown.
In a large study by Baba et al [28], a relation to disease stage has
been described with higher LINE-1 demethylation in more
advanced disease although the differences were very minor. Also,
according to the study’s results, LINE methylation levels were
higher in stage II disease compared to stage I. This study analyzed
whole tissue sections without using microdissection. One of the
reasons that differences were small and stage II showed higher
LINE-1 methylation may be the degree of mesenchymal cell DNA
contamination in the specimen DNA. Our results demonstrated
that not only adjacent normal mucosa, but also mesenchymal cells
in cancer, show about one-third of LINE-1 hypomethylation. This
supports our emphasis that specific target cell isolation is
necessary. Prognostic value of LINE-1 methylation levels in
CRC has been reported [29]; however, variation between tumors
may be a result of the stromal/mesenchymal component
contamination [30].
Our study shows a clear stepwise positive linear relation of
loss of LINE-1 methylation to T-, N-, as well as M-stage. The
levels of LINE-1 demethylation may therefore be helpful in
several clinical situations. Preoperative analysis of CRCs biopsy
material that can predict T-stage (Tis vs. T1 or T1 vs. T2) may
be of use to decide whether endoscopic resection (i.e. transanal
mucosal excision of rectal cancers) may be attempted versus
open resection surgery, which is associated with much higher
morbidity/mortality rates. N-stage prediction could be used to
select CRC patients to test the effectiveness of neoadjuvant
therapy. Furthermore, M-stage prediction may be used as a
biomarker to undertake further metastatic preoperative imaging
with PET-CT scan in addition to the standard work-up. To
assess whether preoperative tumor biopsy material from the
luminal side is representative, we assessed tumor heterogeneity.
The comparison between the deepest part and the surface of
the tumor revealed that tumor heterogeneity of LINE-1
methylation status is relatively subtle. The results suggest that
CRC biopsy specimens collected during colonoscopy are
representative and can be used for assessment of a tumor’s
LINE-1 methylation status analysis. The mean LHI differed
significantly between node positive and node negative CRCs;
whereby ROC analysis showed discriminatory results. There
w a so v e r l a po fL H Iv a l u e sb e t w e e nt h eN + and N0 categories
and the sensitivity and specificity were relatively low. This was
also seen for T- and M-stage discrimination. Larger studies are
needed to determine the utility of LHI as a single biomarker or
combination with other biomarkers.
In conclusion, the study demonstrated that LINE-1 methyl-
ation status correlates with pathological stage of CRC.
Furthermore, its accurate analysis with LCM or equivalent
Figure 6. Receiver-operator characteristic (ROC) curve indicat-
ing the discriminatory accuracy of presence of nodal involve-
ment by LHI. The x-axis represents 1-specificity and the y-axis
sensitivity. The area under the curve (AUC) was calculated to 0.69.
P=0.003.
doi:10.1371/journal.pone.0018884.g006
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surrounding tumor cells clearly can influence results. The onset
of LINE-1 demethylation occurs very early when normal
colorectal mucosa develops into an adenoma with low or
intermediate dysplasia. The results showed a clear and
significant linear correlation of progression of loss of methyl-
ation LINE-1 element to progression of CRC disease (Figure 7)
with regard to T- as well as N- and M-stage. These findings
suggest continuous loss of genomic methylation during CRC
development, which indicates that high epigenomic and thus
genomic events are key features of tumor progression.
Materials and Methods
Measurement of LINE-1 hypomethylation
The methylation status of LINE-1 was evaluated by AQAMA
assay for accurate assessment of CpG island methylation levels
[31]. Before performing the AQAMA assay of LINE-1 methyla-
tion status, SBM was applied on each DNA sample as previously
described [32]. AQAMA requires one forward and one reverse
primer which will amplify the target sequence independent from
the methylation status, as those forward and reverse primer sets do
not contain any CpG. The methylation status is assessed by two
minor-groove-binding (MGB) molecule containing probes (Ap-
plied Biosystems): one methylation specific and one unmethylation
specific. The 5’ primer, 3’ primer, methylation-specific probe and
unmethylation-specific probe are listed as follows: 5’-GGGT-
TTATTTTATTAGGGAGTGTTAGA-3’ (forward), 5’-TCA-
CCCCTTTCTTTA ACTCAAA-3’ (reverse), FAM-5’-TGCGC-
GAGTCGAAGT-3’-MGB-BHQ and VIC-5’-TGTGTG AGTT-
GAAGTAGGG-3’-MGB-BHQ. The reaction mixture for each
AQAMA PCR consisted of DNA template, 0.4 mmol/L of the
forward and reverse primer, 1.4 units of iTaq DNA polymerase
(Bio-Rad, Hercules, CA), 350 mmol/L of each deoxynucleotide
triphosphate and 0.025 pmol of each MGB probe with 5 mmol/L
Mg
2+. PCR amplification was performed with pre-cycle heat
activation of DNA polymerase at 95uC for 10 min, followed by 40
cycles of denaturation at 95uC for 15 sec, annealing and extension
at 60uC for 60 sec. The absolute copy number in each sample was
determined using a standard curve established by amplifying six
aliquot duplicates of templates with known copy numbers (10
*6 to
10
*1 copies). We have previously described the methods for
synthesis of the standard sample of known copy number in the
AQAMA assay [31]. For a negative control, the assay reaction
contained universal unmethylated control DNA that was synthe-
sized as described in a previously published study [13]. For a
positive control, we used universal methylated control DNA
extracted from peripheral blood lymphocytes from a healthy
donor and treated with sssI methyltransferase. Briefly, SssI methyltrans-
ferase treated, bisulfite modified, donor PBL DNA was amplified by
PCR with the primer set to create the standard sample for fully
methylated LINE-1. For construction of the standard sample for
unmethylated LINE-1 we used universal unmethylated control
DNA, prepared as previously described [13]. The completely
methylated and unmethylated PCR product was ligated into a
pCR 2.1-TOPO cloning vector (Invitrogen); the clones were
transformed into Escherichia coli DH5-a cells; and cultures were
expanded as described previously [33]. Plasmids containing the
target gene were purified and quantified by UV spectrophotom-
etry. This was used to make dilution series of known copy number
to construct standard curves for absolute quantification. All
quantitative PCR assays were performed in a blinded fashion
without knowledge of specimen identity. Mean values were
calculated from triplicate reactions. LINE-1 hypomethylation
index (LHI) of each sample was calculated as follows: LINE-1
LHI = unmethylated copy number/(methylated copy number +
unmethylated copy number).
LCM
LCM was used for DNA sample collection for all experiments in
our study. Principles and technical basis of LCM are described in
detail by Fend F et al. [34]. Cells were collected with LCM system
which harbours a digital camera system that detects the selected
cells. This enables that the same amount of square micrometers of
cells can be picked up for each sample.
In-situ SBM assay optimization
To measure LINE-1 hypomethylation index after microdissec-
tion using LCM, we developed the in-situ SBM procedure based on
previously introduced on-slide SBM technique. In-situ SBM was
designed to analyze methylation status of genes in small amount of
DNA obtained from formalin fixed PEAT. In-situ SBM aims to
eliminate DNA isolation and purification steps that are performed
before the actual SBM in the classic procedure which is the main
cause of DNA loss. In-situ SBM contains three steps; denaturing of
DNA, SBM and collection of modified DNA. First, the cells were
microdissected from deparaffinized and rehydrated tissue sections
that stick on the cap used in LCM are incubated in 0.2 mol/L
NaOH at room temperature for 15 min. Then the samples on the
cap are incubated in 3 mol/L sodium bisulfite solution with
0.5 mmol/L hydroquinone (pH 5) in the dark. Three incubation
setting were tested regarding the conversion rates (the rate of
modification of cytosine to uracil) and yields of modified DNA and
incubation setting of 60uC for 8 hrs was chosen as optimal (see
Results Section). After incubation, samples on the cap were rinsed
with distilled water, soaked in 0.3 mol/L NaOH for 15 min to
desulfonate the modified cytosines, and then desalted in distilled
water at 60uC for 2 hrs. Finally, 50 mL lysis buffer containing 4 mg
proteinase K, 2.5% Tween 20, 50 mmol/L Tris, and 1 mmol/L
EDTA were added on the cap and incubated at 50uC for 24 hrs
followed by heat deactivation of proteinase K at 95uC for 10 min.
In each subsequent AQAMA reaction, 1–2 mL lysate was used as a
template without DNA purification.
Ethics Statement
PEAT samples of CRC were obtained from patients who
underwent colectomy or proctectomy between 1995 and 1998 at
Figure 7. Representation of the relation between decreasing
LINE-1 methylation and CRC progression.
doi:10.1371/journal.pone.0018884.g007
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Monica, CA. The study was reviewed and approved by Saint
John’s Health Center/John Wayne Cancer Institute’ Institutional
Review Board (IRB) and Western IRB. Written consent was
obtained from the patients.
PEAT CRC specimens
All tissue specimens had been fixed in 10% buffered formalin
for 24 hrs and paraffin-embedded. For LCM followed by in-situ
SBM and LINE-1 methylation analysis by AQAMA, sections
(4 mm) were cut with a microtome from each PEAT block. Cells
were collected with the VeritasH automated LCM system (Life
Technologies). One of the advantages of this system is that it
enables control of the square micrometers of cells that are picked
up for each sample. To assess the differences of LINE-1
methylation status between normal mucosa, adenoma, cancer
and cancer mesenchymal connective tissue, 25 samples of early
CRC in adenoma (TisN0M0) were selected by a pathologist
(R.R.T.) specialized in CRC that contained all four of these tissue
categories. To study malignant alteration, 94 surgically resected
CRC specimens were procured to investigate the alteration of
LINE-1 methylation status in accordance with cancer progression.
LCM was performed on both study groups. The correlation
between clinico-pathological stage such as T stage, nodal status
and Dukes stage and LINE-1 methylation index were analyzed.
Statistical analysis
All data are expressed as mean+/2S.D., and percentages as
appropriate. Mean value of LHI between two groups such as
adenoma and early cancer, node negative and node positive were
compared using Student’s t-test.
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